| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | 38RL9AE51Q |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| ANTAGONIST | Interferon-alpha/beta receptor alpha chain antagonist |
| Primary Target | |
|---|---|
| interferon α/β receptor 1 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Lupus Nephritis | 3 | D008181 | ClinicalTrials |
| Lupus Erythematosus, Cutaneous | 3 | D008178 | ClinicalTrials |
| Hidradenitis Suppurativa | 2 | D017497 | ClinicalTrials |
| Sjogren's Syndrome | 2 | D012859 | ClinicalTrials |
| Vitiligo | 2 | D014820 | ClinicalTrials |
| Arthritis, Rheumatoid | 2 | D001172 | ClinicalTrials |
| Scleroderma, Localized | 1 | D012594 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 1326232-46-5 |
| ChEMBL | CHEMBL2364653 |
| FDA SRS | 38RL9AE51Q |
| Guide to Pharmacology | 8258 |
CONTENTS